Download Files:
AS-Patisiran
$160 – $680
Products Details
Product Description
– Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis[1][2][3].
Web ID
– HY-153609
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture)
Shipping
– Blue Ice
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– N/A
References
– [1]Adams D, et, al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21.|[2]Hoy SM. Patisiran: First Global Approval. Drugs. 2018 Oct;78(15):1625-1631.|[3]Kristen AV, et, al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019 Feb;9(1):5-23.
Molecular Weight
– 6661.30
Compound Purity
– 92.51
SMILES
– [AS-Patisiran]
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– H2O : ≥ 100 mg/mL
Target
– Small Interfering RNA (siRNA);Transthyretin (TTR)
Pathway
– Epigenetics;Neuronal Signaling
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
Related Products
1000 in stock
1000 in stock
